Clovis Oncology Inc. (CLVS) Stock Rating Reaffirmed by Stifel Nicolaus
Clovis Oncology Inc. (NASDAQ:CLVS)‘s stock had its “buy” rating reissued by investment analysts at Stifel Nicolaus in a report released on Monday. They currently have a $45.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 40.01% from the company’s current price.
Other analysts also recently issued reports about the stock. Piper Jaffray Cos. set a $14.00 price objective on shares of Clovis Oncology and gave the stock a “hold” rating in a report on Thursday, August 18th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $13.00 price objective on shares of Clovis Oncology in a report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Thursday, August 11th. SunTrust Banks Inc. initiated coverage on shares of Clovis Oncology in a research note on Friday, August 5th. They set a “buy” rating and a $25.00 target price for the company. Finally, Credit Suisse Group AG reiterated a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, July 12th. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $36.39.
Clovis Oncology (NASDAQ:CLVS) traded down 0.06% on Monday, reaching $31.79. 1,201,641 shares of the company’s stock were exchanged. Clovis Oncology has a 12 month low of $11.57 and a 12 month high of $109.18. The firm’s market capitalization is $1.22 billion. The firm has a 50-day moving average of $31.11 and a 200-day moving average of $19.16.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/clovis-oncology-inc-clvs-stock-rating-reaffirmed-by-stifel-nicolaus.html
Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.13) by $0.06. During the same quarter in the prior year, the company earned ($2.10) EPS. On average, equities analysts expect that Clovis Oncology will post ($9.25) earnings per share for the current year.
Large investors have recently made changes to their positions in the company. Parametric Portfolio Associates LLC purchased a new stake in shares of Clovis Oncology during the second quarter worth about $144,000. Fox Run Management L.L.C. purchased a new stake in shares of Clovis Oncology during the second quarter worth about $154,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Clovis Oncology during the first quarter worth about $233,000. Royal Bank of Canada boosted its stake in shares of Clovis Oncology by 2,075.9% in the second quarter. Royal Bank of Canada now owns 18,212 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 17,375 shares during the period. Finally, American International Group Inc. boosted its stake in shares of Clovis Oncology by 12.4% in the second quarter. American International Group Inc. now owns 18,297 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 2,016 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.